{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:32:41Z","timestamp":1791689561872,"version":"4.3.4"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p> The advent of bisphosphonates (BPs) has revolutionised the outcome of <jats:italic>Osteogenesis imperfecta<\/jats:italic> (OI) in the last few years. There has always been a safety concern regarding zoledronate\u2019s use due to a paucity of studies. The current study is a retrospective evaluation of children with OI on the short- and long-term side effects of zoledronate and the frequency of fractures per year after the drug was introduced.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p> A total of 26 children diagnosed with OI, with a median age of 84 (45\u2013121) months were enrolled in the study. They received cyclical zoledronate for a median duration of 36 (11\u201361) months at quarterly intervals between January 2008 and December 2014. Safety evaluation involved assessment of its short- and long-term effects in addition to the frequency of fractures after its usage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p> One (3%) neonate had symptomatic hypocalcemia 15 days after the infusion. Three children (11%) had acute phase reactions. None had long-term side effects, including osteonecrosis of the jaw, in our 7-year experience. OI of types III and IV (total of 22) had significant reductions in the number of fractures (p&lt;0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p> Further long-duration studies are necessary to evaluate the longterm safety of zoledronate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2015-0351","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T10:01:26Z","timestamp":1464429686000},"page":"947-952","source":"Crossref","is-referenced-by-count":20,"title":["Zoledronate for <i>Osteogenesis imperfecta<\/i>: evaluation of safety profile in children"],"prefix":"10.1515","volume":"29","author":[{"given":"Chanchal","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pediatrics , Post Graduate Institute of Medical Education and Research , Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inusha","family":"Panigrahi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Post Graduate Institute of Medical Education and Research , Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Somasekhara Aradhya","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Post Graduate Institute of Medical Education and Research , Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu Lal","family":"Meena","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Post Graduate Institute of Medical Education and Research , Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Khandelwal","sequence":"additional","affiliation":[{"name":"Department of Radio diagnosis , Post Graduate Institute of Medical Education and Research , Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,5,28]]},"reference":[{"key":"2023040100561079299_j_jpem-2015-0351_ref_001_w2aab2b8c10b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Brown JJ, Zacharin MR. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab 2009;22:55\u201363.","DOI":"10.1515\/JPEM.2009.22.1.55"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_002_w2aab2b8c10b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared to pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2012;25:485\u201391.","DOI":"10.1515\/jpem-2012-0016"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_003_w2aab2b8c10b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Maines E, Monti E, Doro F, Morandi G, Cavarzere P, et al. Children and adolescents treated with neridronate for OI show no evidence of any osteonecrosis of the jaw. J Bone Miner Metab 2012;30:434\u20138.","DOI":"10.1007\/s00774-011-0331-3"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_004_w2aab2b8c10b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Valadares ER, Carneiro TB, Santos PM, Oliveira AC, Zabel B. What is new in genetics and osteogenesis imperfect classification? J Pediatr (Rio J) 2014;90:536\u201341.","DOI":"10.1016\/j.jped.2014.05.003"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_005_w2aab2b8c10b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Cole WG. The molecular pathology of osteogenesis imperfecta. Clin Orthop Relat Res 1997;343:235\u201348.","DOI":"10.1097\/00003086-199710000-00034"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_006_w2aab2b8c10b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf 2010;2:121\u201337.","DOI":"10.2147\/DHPS.S6285"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_007_w2aab2b8c10b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653\u201361.","DOI":"10.1056\/NEJMoa011807"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_008_w2aab2b8c10b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363\u201374.","DOI":"10.1172\/JCI6800"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_009_w2aab2b8c10b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 2005;280: 7317\u201325.","DOI":"10.1074\/jbc.M412817200"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_010_w2aab2b8c10b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Munns CF, Rajab MH, Hong J, Briody J, H\u00f6gler W, et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 2007;41:366\u201370.","DOI":"10.1016\/j.bone.2007.05.002"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_011_w2aab2b8c10b1b7b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"H\u00f6gler W, Yap F, Little D, Ambler G, McQuade M, et al. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004;145:701\u20134.","DOI":"10.1016\/j.jpeds.2004.06.066"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_012_w2aab2b8c10b1b7b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Nicolaou N, Agrawal Y, Padman M, Fernandes JA, Bell MJ. Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates. J Child Orthop 2012;6:21\u20137.","DOI":"10.1007\/s11832-011-0380-0"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_013_w2aab2b8c10b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16:101\u201316.","DOI":"10.1136\/jmg.16.2.101"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_014_w2aab2b8c10b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Sillence DO. Osteogenesis imperfecta: an expanding panorama of variants. Clin Orthop 1981;159:11\u201325.","DOI":"10.1097\/00003086-198109000-00004"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_015_w2aab2b8c10b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A 2011;155A:943\u201368.","DOI":"10.1002\/ajmg.a.33909"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_016_w2aab2b8c10b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Chennuru S, Koduri J, Bauman MA. Risk factors for symptomatic hypocalcemia complicating treatment with zoledronic acid. Intern Med J 2008;38:635\u20137.","DOI":"10.1111\/j.1445-5994.2007.01580.x"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_017_w2aab2b8c10b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis: HORIZON Pivotal Fracture Trial. N Engl J Med 2007;356:1809\u201322.","DOI":"10.1056\/NEJMoa067312"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_018_w2aab2b8c10b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005;39:101\u201311.","DOI":"10.1111\/j.1365-2249.2005.02665.x"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_019_w2aab2b8c10b1b7b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, et al. Serum 25-hydroxyvitamin D levels modulate the acute phase response associated with the first nitrogen containing bisphosphonate infusion. J Bone Miner Res 2009;25:447\u201354.","DOI":"10.1359\/jbmr.090819"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_020_w2aab2b8c10b1b7b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012;172:930\u20136.","DOI":"10.1001\/archinternmed.2012.1796"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_021_w2aab2b8c10b1b7b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Fedele S, Kumar N, Davies R, Fiske J, Greening S, et al. Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Dis 2009;15:527\u201337.","DOI":"10.1111\/j.1601-0825.2009.01581.x"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_022_w2aab2b8c10b1b7b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Hennedige AH, Jayasinghe J, Khajeh J, Macfarlane TV. Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res 2013;4:e1.","DOI":"10.5037\/jomr.2013.4401"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_023_w2aab2b8c10b1b7b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Brown JJ, Ramalingam L, Zacharin MR. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol (Oxf) 2008;68:863\u20137.","DOI":"10.1111\/j.1365-2265.2008.03189.x"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_024_w2aab2b8c10b1b7b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Lu Y, Zhao F, Ren X, Li Z, Yang X, et al. A rare case of osteogenesis imperfecta combined with complete tooth loss. J Pediatr Endocrinol Metab 2014;27:143\u20137.","DOI":"10.1515\/jpem-2013-0069"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_025_w2aab2b8c10b1b7b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N. Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab 2010;28:451\u20135.","DOI":"10.1007\/s00774-009-0149-4"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_026_w2aab2b8c10b1b7b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2014;7:CD005088.","DOI":"10.1002\/14651858.CD005088.pub3"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_027_w2aab2b8c10b1b7b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Renaud A, Aucourt J, Weill J, Bigot J, Dieux A, et al. Radiographic features of osteogenesis imperfecta. Insights Imaging 2013;4:417\u201329.","DOI":"10.1007\/s13244-013-0258-4"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_028_w2aab2b8c10b1b7b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"van Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphanates. Radiology 1992;184:249\u201354.","DOI":"10.1148\/radiology.184.1.1609087"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_029_w2aab2b8c10b1b7b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Al Muderis M, Azzopardi T, Cundy P. Zebra lines of Pamidronate therapy in children. J Bone Joint Surg Am 2007;89A:1511\u20136.","DOI":"10.2106\/JBJS.F.00726"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_030_w2aab2b8c10b1b7b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002;110:1293\u20139.","DOI":"10.1172\/JCI0215952"},{"key":"2023040100561079299_j_jpem-2015-0351_ref_031_w2aab2b8c10b1b7b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Drake TM, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83:1032\u201345.","DOI":"10.4065\/83.9.1032"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2015-0351\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2015-0351\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T17:19:53Z","timestamp":1680369593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2015-0351\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,28]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,5,16]]},"published-print":{"date-parts":[[2016,8,1]]}},"alternative-id":["10.1515\/jpem-2015-0351"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2015-0351","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5,28]]}}}